Terms: = Head and neck cancer AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715
111 results:
1. Correlation of primary tumor volume and histopathologic response following neoadjuvant treatment of esophageal adenocarcinoma.
Bremm J; Brunner S; Celik E; Damanakis A; Schlösser H; Fuchs HF; Schmidt T; Zander T; Maintz D; Bruns CJ; Quaas A; Pinto Dos Santos D; Schroeder W
Eur J Surg Oncol; 2024 Apr; 50(4):108003. PubMed ID: 38401351
[TBL] [Abstract] [Full Text] [Related]
2. SCUBE3 Exerts a Tumor-Promoting Effect in Tongue Squamous Cell Carcinoma by Promoting cebpa Binding to the CCL2 Promoter.
Zhu M; Ma Y; Wang W; Li M; Chen S; Liu F; Shi X; Bi H; Zhang C; Nie F; Zheng H; Zhang C
Mol Cancer Res; 2024 May; 22(5):482-494. PubMed ID: 38349738
[TBL] [Abstract] [Full Text] [Related]
3. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
Huang D; Zeng D; Tang Y; Jiang L; Yang Q
Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
[TBL] [Abstract] [Full Text] [Related]
4. Future cancer risk after urgent suspected cancer referral in England when cancer is not found: a national cohort study.
Scott SE; Gildea C; Nicholson BD; Evans RE; Waller J; Smith D; Purushotham A; Round T
Lancet Oncol; 2023 Nov; 24(11):1242-1251. PubMed ID: 37922929
[TBL] [Abstract] [Full Text] [Related]
5. Obtaining SF-6D utilities from FACT-H&N in thyroid carcinoma patients: development and results from a mapping study.
Yang Q; Huang D; Jiang L; Tang Y; Zeng D
Front Endocrinol (Lausanne); 2023; 14():1160882. PubMed ID: 37664851
[TBL] [Abstract] [Full Text] [Related]
6. Overuse of thyroid ultrasound.
Acosta GJ; Singh Ospina N; Brito JP
Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):225-230. PubMed ID: 37288725
[TBL] [Abstract] [Full Text] [Related]
7. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
[TBL] [Abstract] [Full Text] [Related]
8. The Use of Antibiotics During Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Advanced Esophagogastric cancer.
Zhang L; Kuang T; Chai D; Deng W; Wang P; Wang W
Int Immunopharmacol; 2023 Jun; 119():110200. PubMed ID: 37099942
[TBL] [Abstract] [Full Text] [Related]
9. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Park K; Sabari JK; Haura EB; Shu CA; Spira A; Salgia R; Reckamp KL; Sanborn RE; Govindan R; Bauml JM; Curtin JC; Xie J; Roshak A; Lorenzini P; Millington D; Thayu M; Knoblauch RE; Cho BC
Lung Cancer; 2023 Apr; 178():166-171. PubMed ID: 36868177
[TBL] [Abstract] [Full Text] [Related]
10. Lnc-17Rik promotes the immunosuppressive function of Myeloid-Derived suppressive cells in esophageal cancer.
Wen J; Xuan B; Gao Y; Liu Y; Wang L; He L; Meng X; Zhou T; Tao Y; Guo K; Wang Y
Cell Immunol; 2023 Mar; 385():104676. PubMed ID: 36780770
[TBL] [Abstract] [Full Text] [Related]
11. Does Milan affect management? A retrospective analysis of resection rate and time to surgery among Milan categories.
Tenney TB; Mullane PC; Viswanathan K; Shi Q; Lui SK; Lubin DJ
Diagn Cytopathol; 2023 Apr; 51(4):221-229. PubMed ID: 36700488
[TBL] [Abstract] [Full Text] [Related]
12. Diagnostic performance of simplified TI-RADS for malignant thyroid nodules: comparison with 2017 ACR-TI-RADS and 2020 C-TI-RADS.
Chen Z; Du Y; Cheng L; Zhang Y; Zheng S; Li R; Zhang W; Zhang W; He W
Cancer Imaging; 2022 Aug; 22(1):41. PubMed ID: 35978376
[TBL] [Abstract] [Full Text] [Related]
13. Low expression of LncRNA-CAF attributed to the high expression of HIF1A in esophageal squamous cell carcinoma and gastric cancer patients.
Bahramian S; Sahebi R; Roohinejad Z; Delshad E; Javid N; Amini A; Razavi AE; Shafiee M; Shamsabadi FT
Mol Biol Rep; 2022 Feb; 49(2):895-905. PubMed ID: 35040008
[TBL] [Abstract] [Full Text] [Related]
14. Endoscopic Cervical Lymph Node Dissection Using the Extra-cervical Anterior Chest Wall Approach: A New Technique.
Elzahaby IA; Shetiwy M; Hossam A; Elafy A
Surg Innov; 2022 Dec; 29(6):723-729. PubMed ID: 34823394
[TBL] [Abstract] [Full Text] [Related]
15. METTL3/14 and IL-17 signaling contribute to cebpa-DT enhanced oral cancer cisplatin resistance.
Qiao X; Zhu L; Song R; Shang C; Guo Y
Oral Dis; 2023 Apr; 29(3):942-956. PubMed ID: 34807506
[TBL] [Abstract] [Full Text] [Related]
16. Long noncoding RNA cebpa-DT promotes cisplatin chemo-resistance through cebpa/BCL2 mediated apoptosis in oral squamous cellular cancer.
Qiao X; Liu J; Zhu L; Song R; Zhong M; Guo Y
Int J Med Sci; 2021; 18(16):3728-3737. PubMed ID: 34790046
[TBL] [Abstract] [Full Text] [Related]
17.
Subramanyam GK; Gaddam SA; Kotakadi VS; Palithya S; Penchalaneni J; Challagundla VN
Artif Cells Nanomed Biotechnol; 2021 Dec; 49(1):635-650. PubMed ID: 34738487
[TBL] [Abstract] [Full Text] [Related]
18. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
Liu R; Liu L; Zhao C; Bai Y; Zheng Y; Zhang S; Li N; Yang J; Fan Q; Wang X; Zeng S; Zhang Y; Zhang W; Zhuang Y; Kang N; Jiang Y; Sun H; Xu J
BMC Gastroenterol; 2021 Oct; 21(1):398. PubMed ID: 34688250
[TBL] [Abstract] [Full Text] [Related]
19. Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma.
Xie J; Wang Z; Fan W; Liu Y; Liu F; Wan X; Liu M; Wang X; Zeng D; Wang Y; He B; Yan M; Zhang Z; Zhang M; Hou Z; Wang C; Kang Z; Fang W; Zhang L; Lam EW; Guo X; Yan J; Zeng Y; Chen M; Liu Q
Signal Transduct Target Ther; 2021 Sep; 6(1):333. PubMed ID: 34482361
[TBL] [Abstract] [Full Text] [Related]
20. cebpB knockdown sensitizes nasopharyngeal carcinoma cells to cisplatin by promoting the expression of serine protease inhibitor Kazal-type 5.
Liu H; Huang Q; Lv Y; Dong Y; Song D
Anticancer Drugs; 2022 Jan; 33(1):e327-e335. PubMed ID: 34387602
[TBL] [Abstract] [Full Text] [Related]
[Next]
